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and adjuvant treatment with epirubicin were relevant pre-
dictors for recurrence-free survival with hazard ratios of 
1.48, 1.38, 1.22, 1.56, and 1.27, respectively. A table for 
recurrence probabilities was developed using these five 
predictors. Based on the probability of recurrence, three 
risk groups were identified. Patients in each of the separate 
risk groups should be scheduled for less or more aggressive 
treatment. The model showed sufficient discrimination and 
good predictive accuracy. External validation showed good 
validity.
Conclusion In our model, we identified five relevant pre-
dictors for recurrence-free survival in IR-NMIBC patients 
treated with intravesical chemotherapy. These recurrence 
predictors allow the urologists to stratify patients in risk 
groups for recurrence that could help in deciding for an 
individualized treatment approach.
Keywords Adjuvant chemotherapy · Intravesical 
administration · Prediction model · Recurrence · Urinary 
bladder neoplasm
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Abstract 
Purpose To develop a model to predict recurrence for 
patients with intermediate-risk (IR) non-muscle-invasive 
bladder cancer (NMIBC) treated with intravesical chemo-
therapy which can be challenging because of the heteroge-
neous characteristics of these patients.
Methods Data from three Dutch trials were combined. 
Patients treated with intravesical chemotherapy with 
characteristics according to the IR definition of the EAU 
guideline 2013 were included. Uni- and multivariable 
Cox regression with selection methods were used to iden-
tify predictors of recurrence at 1, 2, and 5 years. An easy-
readable table for recurrence probabilities was developed. 
An external validation was done using data from Spanish 
patients.
Results A total of 724 patients were available for analy-
ses, of which 305 were primary patients. Recurrences 
occurred in 413 patients (57 %). History of recurrences, 
history of intravesical treatment, grade 2, multiple tumors, 
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Introduction
Bladder cancer remains a common problem in the Western 
world [1]. Approximately 75–85 % of bladder cancer pre-
sents as non-muscle-invasive bladder cancer (NMIBC); the 
remaining patients have muscle-invasive disease (MIBC) 
[2].
Treatment of NMIBC consists of complete transurethral 
resection of the bladder tumor (TURBT), followed by a sin-
gle immediate postoperative instillation (POI) with chemo-
therapy. Further treatment depends on patients’ and tumor 
characteristics. In the guidelines of the European Associa-
tion of Urology (EAU), patients are divided into three risk 
groups [2] (Supplementary Table [ST] 1). This stratifica-
tion is similar to that provided by the International Blad-
der Cancer Group (IBCG) [3] and is partially based on the 
well-known risk tables developed by the European Organi-
zation for Research and Treatment of Cancer (EORTC) [4].
In general, treatment advises for low-risk and high-risk 
groups are clearly stated in the guidelines, but treatment 
advises for intermediate-risk (IR) patients are less clear. This 
is an important lack of information as the IR group covers a 
large number of patients with heterogeneous characteristics, 
making selection of appropriate therapy challenging. There-
fore, we identified predictors of recurrence and developed a 
prediction model for recurrence probabilities for IR-NMIBC 
patients treated with intravesical chemotherapy.
Methods
Data of three prospective Dutch studies [5–7] were avail-
able for analyses, providing us with individual data of 2006 
patients. Treatment and follow-up have been described in 
detail before [5–7] and can be found in ST2.
For the development of the prediction model, in this 
study, we included only patients with Ta G1/2 urothelial 
carcinoma without carcinoma in situ (CIS) and without the 
combination ‘multiple & recurrent & diameter >3 cm.’ This 
is consistent with the definition of IR group according to 
the EAU guideline [2]. All included patients received intra-
vesical chemotherapy (either mitomycin C or epirubicin).
Primary outcome measurement was time to first recur-
rence (recurrence-free survival; RFS): time from randomi-
zation to the date of the first bladder recurrence.
Statistical methods
First, baseline demographics of the selected Dutch patients 
are presented (n = 724).
Univariable and multivariable Cox regression with 
selection procedures and likelihood analyses were used 
for selecting independent variables for RFS. Smoking and 
tumor diameter were removed from analyses based on the 
number of missing data and the hazard ratios (HRs). For 
the final model, the adjusted HRs are presented, including 
the 1, 2, and 5 years probabilities for recurrence. To assess 
the model’s accuracy (discrimination), Harrell’s bias cor-
rected concordance index (c-index) was calculated at 1, 2, 
and 5 years and models were refitted 200 times with boot-
strap resampling techniques.
Three risk groups were constructed based on the risk 
profiles of the final model: <P33, P33–P66, and >P66. In 
addition, sensitivity, specificity, negative, and positive pre-
dictive value (NPV, PPV) were calculated for the minor 
risk group at 2 years, as most recurrences occurred within 
2 years.
External validation
Prospectively collected, independent, individual patient 
data provided by Fundacio Puigvert, Barcelona, Spain, 
were used to study the final prediction model (n = 137). 
However, this cohort included only data of primary 
patients. For the comparison, we used a subcohort of pri-
mary patients from the Dutch cohort (n = 305). The predic-
tion model was applied to the data of these cohorts.
Statistical analyses were done with SPSS 20.0.0 for 
Windows (SPSS Inc., Chicago, Il, USA), in SAS 9.2 for 
Windows (SAS Institute Inc., Cary, NC, USA) and in R 2.2 
for Windows.
Results
Demographics of Dutch cohort
Data of 724 Dutch patients met our inclusion criteria. 
The baseline demographics are presented in Table 1. The 
median follow-up was 29.6 months (range 2–239 months). 
A total of 413 patients (57 %) experienced a recurrence. 
As expected, only few patients progressed to MIBC (16 
patients; 2.2 %), and therefore, we did not take progression 
into account as an outcome measurement.
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Recurrence
In Tables 2 and 3, we show the crude and adjusted HR 
with 95 % confidence interval (CI) of the clinicopatho-
logical characteristics using uni- and multivariable Cox 
regression. The following five variables were included in 
the final model: history of previous recurrences, history 
of intravesical treatment, tumor grade 2, multiple tumors, 
and adjuvant treatment with epirubicin, with HRs of 1.48, 
1.38, 1.22, 1.56, and 1.27, respectively. As can be seen 
in Table 3, the HR, 95 % CI and p value of tumor grade 
and adjuvant treatment are 1.22 (95 % CI 0.99–1.51; p 
value 0.061) and 1.27 (95 % CI 1.00–1.62; p value 0.048), 
respectively. Although the statistical significance of these 
two variables is around 0.05, the five-variable model out-
performed the three-variable model, i.e., the model without 
tumor grade and adjuvant treatment (likelihood ratio test, 
Chi-square = 17.0, p = 0.0002). 
Prediction model
The recurrence probabilities of the final Cox regres-
sion model at 1, 2, and 5 years are presented in Table 4. 
The c-index for this RFS model was 0.60, 0.62, and 
0.63 at year 1, 2, and 5, respectively. Three risk groups 
were constructed based on the risk profiles of the final 
model. The Kaplan–Meier curves of minor, moderate, 
and major risk based on the risk profiles of the final 
model are shown in Fig. 1. The model can distinguish 
clearly between recurrence outcomes, e.g., a patient 
with multiple G2 recurrences without previous treat-
ment who received adjuvant treatment with epirubicin 
Table 1  Demographics of the three cohorts
CI confidence interval, HR hazard ratio, NA not applicable for primary patients
Dutch cohort Dutch subcohort of primary patient Spanish cohort
Total (n = 724) Recurrence (n = 413) Total (n = 305) Recurrence (n = 148) Total (n = 137) Recurrence (n = 79)
N (%)/ N (%)/ N (%)/ N (%)/ N (%)/ N (%)/
Median (range) Median (range) Median (range) Median (range) Median (range) Median (range)
Age in years 67.5 (33–89) 66.9 (35–86) 65 (33–86) 64.9 (35–85) 69 (37–89) 69 (37–84)
Age classification
 ≤66 year 335 (46) 195 (47) 161 (53) 78 (53) 61 (45) 37 (47)
 >66 year 389 (54) 218 (53) 144 (47) 70 (47) 76 (55) 42 (53)
Gender
 Male 592 (82 337 (82) 246 (81) 117 (79) 109 (80) 61 (77)
 Female 130 (18 74 (18) 59 (19) 31 (21) 28 (20) 18 (23)
 Unknown 2 2 0 0 0 0
Primary or recurrent
 Primary 305 (42) 148 (36) 305 (100) 148 (100) 137 (100) 79 (100)
 Recurrent 419 (58) 265 (64) NA NA NA NA
History of intravesical treatment
 No 580 (84) 309 (79) 305 (100) 148 (100) 317 (100) 79 (100)
 Yes 115 (16) 83 (21) NA NA NA NA
 Unknown 29 21
Tumor grade
 G1 351 (48) 205 (50) 102 (33) 51 (35) 14 (10) 10 (13)
 G2 373 (52) 208 (50) 203 (67) 97 (65) 123 (90) 69 (87)
Number of tumors
 Single 176 (25) 83 (20) 57 (19) 23 (16) 85 (63) 42 (54)
 Multiple 542 (75) 324 (80) 248 (81) 125 (84) 50 (37) 36 (46
 Unknown 6 6 0 0 2 1
Adjuvant treatment
 Mitomycin C 218 (30) 113 (27) 105 (34) 46 (31) 137 (100) 79 (100)
 Epirubicin 506 (70) 300 (73) 200 (66) 102 (69) 0 0
Median follow-up in 
mo (range)
29.6 (2–239) 19.2 (2–239) 37.2 (2–128) 21 (2–128) 30.6 (3–112) 18.4 (3–97)
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has, according to Table 4, 67 % chance of being recur-
rence free at 12 months, which is associated with major 
risk in Fig. 1. We calculated sensitivity, specificity, PPV, 
and NPV for minor risk patients at 2 years (ST3). PPV is 
68.4 % and NPV is 65.2 %.
Demographics of Spanish cohort and external 
validation
For the external validation, a cohort of 137 Spanish patients 
was used (treatment and demographics can be found in ST2 
and Table 1, respectively). It needs to be stressed that in the 
Spanish cohort, only ten patients had grade 1. Therefore, 
only the HR of the number of tumors was updated using 
the data of Dutch subcohort and the Spanish cohort. The 
HR of the number of tumors of 1.65 (95 % CI 1.28–2.00) in 
the combined cohorts (Dutch subcohort + Spanish cohort) 
was comparable to the development (Dutch) cohort: 1.56 
(95 % CI 1.20–2.01). The associated Kaplan–Meier curves 
are shown in Fig. 2.
Discussion
We present a study comparing recurrence outcome and 
treatment options for the heterogeneous spectrum of IR 
patients, and we propose a prediction model on recurrence 
probabilities with external validation. We found five rel-
evant predictors for RFS: a history of recurrences, history 
of previous treatment, tumor grade 2, multiple tumors, and 
adjuvant treatment with epirubicin, with HRs of 1.48, 1.38, 
1.22, 1.56, and 1.27, respectively. There is a huge difference 
between 1 and 5 years outcome, and between having none 
or all of the independent predictors (Table 4). We defined 
Table 2  Crude hazard ratios (HRs) and the 95 % confidence intervals (CI), using univariable Cox regression for time to recurrence for the three 
cohorts
NA not applicable to primary patients; – no data available due to 100 % treatment with mitomycin C
Dutch cohort (n = 724) Dutch subcohort of primary patients 
(n = 305)
Spanish cohort (n = 137)
N HR 95 % CI p value N HR 95 % CI p value N HR 95 % CI p value
Age
 ≤66 year 722 1 (ref) 305 1 (ref) 137 1 (ref)
 >66 year 1 (0.83–1.22) 0.978 1.05 (0.76–1.45) 0.774 0.92 (0.59–1.43) 0.703
Gender
 Male 720 1 (ref) 305 1 (ref) 137 1 (ref)
 Female 0.98 (0.76–1.26) 0.854 1.07 (0.72–1.58) 0.742 1.25 0.74–2.21) 0.407
Primary or recurrent
 Primary 722 1 (ref) NA NA NA NA NA NA NA NA
 Recurrent 1.54 (1.25–1.88) <0.001
History of intravesical treatment
 No 694 1 (ref) NA NA NA NA NA NA NA NA
 Yes 1.71 (1.34–2.18) <0.001
Tumor grade
 G1 722 1 (ref) 305 1 (ref) 137 1 (ref)
 G2 1.01 (0.84–1.23) 0.885 1.01 (0.72–1.42) 0.936 0.8 (0.41–1.56) 0.511
Tumor diameter 528 219 123
 ≤30 mm 1 (ref) 0.365 1 (ref) 1 (ref)
 >30 mm 1.2 (0.81–1.79) 1.88 (1.20–2.96) 0.006 0.64 (0.34–1.19) 0.158
Number of tumors
 Single 716 1 (ref) 305 1 (ref) 135 1 (ref)
 Multiple 1.48 (1.16–1.88) 0.002 1.41 (0.90–2.21) 0.129 1.82 (1.16–2.84) 0.009
Smoking status 499 198 118
 No 1 (ref) 0.15 1 (ref) 1 (ref)
 Yes in past or now 1.28 (0.91–1.81) 1.68 (0.94–3.01) 0.08 0.79 (0.45–1.39) 0.411
Treatment
 Mitomycin C 722 1 (ref) 0.006 305 1 (ref) 0.11 – – –
 Epirubicin 1.36 (1.09–1.69) 1.33 (0.94–1.89)
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the IR group into three subgroups (minor, moderate, and 
major risk) in a way that each risk group needs to be con-
sidered for a less or more aggressive adjuvant treatment 
schedule or treatment type. The recurrence probabilities as 
predicted in Table 4 can be related to a risk group in Fig. 1.
The EORTC have developed risk tables based on a 
group of 2596 patients [4]. However, the EORTC risk 
tables have several limitations: 22 % of patients received 
no intravesical treatment at all; only 171 patients (7 %) 
received treatment with bacillus Calmette–Guerin (BCG) 
and none received BCG maintenance. Therefore, the 
EORTC risk tables could be interpreted as probabilities of 
the untreated natural history of the disease, especially for 
progression. Another well-known prediction model is the 
scoring model of Club Urologico Español de Tratamiento 
Oncologico (CUETO) [8]. Data of 1062 patients, all treated 
with BCG, were used to identify risk factors for recurrence 
and progression after BCG treatment. Several other predic-
tion models have been developed for NMIBC [9–15], but 
none of them included solely patients who, according to the 
guidelines, should have been and in fact were treated with 
intravesical chemotherapy.
Recently, Kamat et al. [16] developed an algorithm 
specifically for IR patients based on the consensus of the 
IBCG. They consider tumor size, tumor multiplicity, tim-
ing and frequency of recurrences, and previous treatment 
to be key factors. Based on these key factors, they divide 
IR patients in three groups: low-risk patients, ‘true’ IR 
patients, and high-risk patients. Our analyses and model 
support these recommendations; only tumor size, which is 
also a significant predictor in the EORTC risk model [4], is 
of no influence in our model, and tumor grade is not con-
sidered to be a key factor by the IBCG.
Concerning tumor size, Kamat et al. [16] do mention 
that the well-known cutoff of 3 cm might be no longer rel-
evant as the number of patients with large tumors is very 
low, which we could confirm (in the Dutch cohort only 
6 %). Within the IBCG, it was suggested to further study 
a new cutoff of 1 cm. When analyzing this cutoff in our 
cohort, no statistical significant influence on recurrence 
outcome was seen (p = 0.480), but this might be due to the 
high number of missing data, which is a limitation of our 
study.
We found that tumor diameter had many missing data 
and was no statistically significant predictor for RFS in the 
complete cohort. This is clearly different from other predic-
tion models including the EORTC risk model [4], but our 
group of patients all received adjuvant intravesical chem-
otherapy and are therefore not comparable with, e.g., the 
EORTC risk model patients.
The term ‘low grade’ is based on the WHO 2004 grading 
system, which was not yet available during the inclusion 
period of the three Dutch studies. Therefore, we considered 
G1 and G2 tumors to be low grade, but G2 tumors are a 
mixture of low-grade and high-grade tumors. According 
to Chen et al. [17], approximately 80 % of the G2 tumors 
are low grade. Thus, in this study, we could have misclas-
sified 75 patients, and consequently, these patients could be 
treated insufficiently with subsequently more recurrences.
The c-index of our model was 0.60, 0.62 and 0.63 at 
year 1, 2, and 5, respectively. This is comparable to the 
c-index for recurrence probabilities of the EORTC risk 
Table 3  Adjusted hazard 
ratios (HRs) and 95 % 
confidence intervals (CI), using 
multivariable Cox regression 
with selection procedures for 
time to recurrence for the three 
cohorts
NA not applicable to primary patient; – no data available due to 100 % treatment with mitomycin C
Dutch cohort (n = 724) Dutch subcohort of primary 
patients (n = 305)
Spanish cohort (n = 137)
HR (95 % CI) p value HR (95 % CI) p value HR (95 % CI) p value
Primary versus recurrent
 Primary 1 (ref) 0.001 NA (NA) NA NA (NA) NA
 Recurrent 1.48 (1.17–1.88) NA (NA) NA (NA)
History of intravesical treatment
 None 1 (ref) 0.021 NA (NA) NA NA (NA) NA
 Yes 1.38 (1.05–1.80) NA (NA) NA (NA)
Tumor grade
 G1 1 (ref) 0.061 1 (ref) 0.485 1 (ref) 0.861
 G2 1.22 (0.99–1.51) 1.11 (0.78–1.58) 0.94 (0.48–1.85)
No. of tumors
 Single 1 (ref) 0.001 1 (ref) 0.286 1 (ref) 0.011
 Multiple 1.56 (1.20–2.01) 1.47 (0.92–12.34) 1.8 (1.15–2.84)
Treatment
 Mitomycin C 1 (ref) 0.048 1 (ref) 0.278 – –
 Epirubicin 1.27 (1.00–1.62) 1.24 (0.84–1.84) – –
178 World J Urol (2016) 34:173–180
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Tables (0.66 both at 1 and 5 years) and that of the CUETO 
scoring model (0.64 both at 1 and 5 years) [4, 8]. However, 
the clinical relevance of the c-index is doubtful and there 
is no consensus how high the c-index should be to make a 
model clinically relevant.
For a more practical approach, based on their risk fac-
tors, we divided the patients in three subgroups: minor, 
moderate and major risk. As can be seen in Fig. 1, this sub-
division is clearly related to recurrence outcome, and thus, 
the major risk group could be considered for more aggres-
sive treatment and the minor risk group for less aggressive 
treatment. The relevance of this subdivision is also reflected 
in the predictive accuracy of our model (ST3). For treat-
ment options, the NPV and PPV are more important than 
sensitivity and specificity, as this is associated with under- 
and overtreatment. Compared to the EORTC and CUETO, 
our model is clearly better in preventing overtreatment in 
minor risk patients as PPV is much higher (68 % versus 
21 and 24 %), but NPV is somewhat lower (65 versus 94 
and 92 %) which, however, is less of a problem in minor 
risk patients [18]. Additionally, the external validation 
shows very good overlap in HR. However, as the Spanish 
cohort only included primary patients, it is in fact a partial 
external validation. Nevertheless, as agreement between the 
Dutch subcohort and the Spanish cohort is high, one could 
hypothesize that these results could be extrapolated to the 
total model. An external validation with primary and recur-
rent patients is needed to confirm our results.
Limitations of this study are the long inclusion period, 
the missing data, and the differences with the current 
standard of treatment including the quality of TURBT due 
to, e.g., the introduction of re-TURBT, the introduction of 
Table 4  Probabilities of being recurrence free at 1, 2, and 5 years in 
patients with non-muscle-invasive bladder cancer after treatment with 
intravesical chemotherapy





  Mitomycin C 89 (86–93) 85 (80–89) 79 (73–87)
  Epirubicin 87 (82–91) 81 (76–86) 75 (76–83)
 Multiple
  Mitomycin C 84 (79–89) 77 (71–83) 70 (62–79)
  Epirubicin 80 (75–85) 72 (67–77) 63 (56–71)
Grade 2
 Single
  Mitomycin C 87 (83–91) 81 (76–87) 75 (68–84)
  Epirubicin 84 (79–89) 77 (71–83) 70 (62–79)
 Multiple
  Mitomycin C 81 (76–86) 73 (66–80) 64 (56–75)




  Mitomycin C 80 (73–86) 71 (63–79) 62 (52–74)
  Epirubicin 74 (67–82) 64 (57–73) 54 (44–67)
 Multiple
  Mitomycin C 69 (62–77) 58 (50–68) 47 (37–60)
  Epirubicin 63 (56–70) 50 (44–57) 39 (31–49)
Grade 2
 Single
  Mitomycin C 75 (69–82) 65 (57–75) 56 (45–69)
  Epirubicin 69 (62–78) 58 (50–68) 48 (37–61)
 Multiple
  Mitomycin C 64 (57–72) 52 (43–63) 40 (30–54)




  Mitomycin C 68 (60–78) 57 (47–68) 46 (34–61)
  Epirubicin 61 (52–72) 49 (40–59) 37 (27–52)
 Multiple
  Mitomycin C 55 (47–65) 41 (32–53) 30 (20–44)
  Epirubicin 47 (39–55) 33 (26–41) 21 (14–32)
Grade 2
 Single
  Mitomycin C 63 (54–72) 50 (40–62) 39 (28–54)
  Epirubicin 55 (46–66) 41 (32–53) 30 (20–44)
 Multiple
  Mitomycin C 48 (40–58) 34 (25–47) 23 (14–37)
  Epirubicin 40 (33–48) 25 (18–35) 15 (9–25)
Fig. 1  Proportion of recurrence-free patients per risk group
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fluorescence cystoscopy, and the lack of immediate POIs 
in most patients (only 23 % of patients received imme-
diate POI). On the other hand, fluorescence cystoscopy 
is most useful in CIS, but these patients were excluded 
in our analyses. In the Dutch cohort, no re-TURBT was 
done, but this is not always necessary in IR patients. 
Another limitation is the variability in adjuvant treatment, 
including the dose, the concentration of chemotherapy 
used, and the treatment schedule which might have influ-
enced the outcome. Yet, the median number of instilla-
tions received was 10, and only 2.1 % of patients received 
less than six instillations. Furthermore, both European 
and American guidelines do not recommend specific 
chemotherapy schedules [2, 19].
Conclusion
We developed a risk table for IR-NMIBC patients treated 
with intravesical chemotherapy including five relevant 
predictors of RFS: history of recurrences, history of intra-
vesical treatment, grade 2, multiple tumors and adjuvant 
treatment with epirubicin. These individual predictors were 
used to subdivide IR patients into three risk groups, which 
is related to recurrence outcome. With this subcategoriza-
tion, the urologist together with the patient can choose for 
an individualized treatment approach.
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